MedPath

Study which tests 2 medications (SB27, Keytruda) to compare how effective, safe and well tolerated in a large number of metastatic non-squamous non-small cell lung cancer patients

Phase 1
Recruiting
Conditions
on-small Cell Lung Cancer
Therapeutic area: Diseases [C] - Neoplasms [C04]
Registration Number
CTIS2023-507448-36-00
Lead Sponsor
Samsung Bioepis Co. Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
616
Inclusion Criteria

Male or female = 18 years of age, Have been diagnosed with stage IV non-squamous NSCLC, Have not received any prior systemic anti-cancer therapy for metastatic NSCLC, Agree to use adequate methods of contraception

Exclusion Criteria

Unable to take folic acid and vitamin B12 supplementation, Unable to receive chemotherapy during the study

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath